Comparison of aortoiliac disease stenting patency using balloon-expandable, self-expanding, and covered stents - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of Patency Rates in Aortoiliac Disease Stenting: A Comparison of Balloon-Expandable, Self-Expanding, and Covered Stents

  • By

  • Ali A. Hasnie

  • Tonga Nfor

  • James O. Adefisoye

  • Kelly Magee

  • M. Fuad Jan

  • Mark W. Mewissen

  • Tanvir K. Bajwa

  • Babak Haddadian

  • May 13, 2026

Share

  • 1

    Peripheral arterial disease affects approximately 6.5 million individuals in the U.S., with a significant portion located in the iliac arteries.

  • 2

    The study analyzed 1,886 patients from the Vascular Quality Initiative database who underwent aortoiliac artery interventions between 2012 and 2017.

  • 3

    Balloon-expandable stents showed a higher one-year primary patency rate (98.4%) compared to self-expanding (97.1%) and covered stents (96.3%).

  • 4

    At three years, there was no significant difference in primary patency rates among the three stent types, indicating similar long-term outcomes.

  • 5

    Stent selection for aortoiliac interventions should consider factors like cost and lesion characteristics rather than relying solely on long-term patency.

Original Source(s)

Comparison of aortoiliac disease stenting patency using balloon-expandable, self-expanding, and covered stents

  • by Ali A. Hasnie, Tonga Nfor, James O. Adefisoye, Kelly Magee, M. Fuad Jan, Mark W. Mewissen, Tanvir K. Bajwa, Babak Haddadian

  • May 13, 2026

Related Content

QOL After Head and Neck Reconstruction

A prospective cohort study suggests that clinically meaningful quality‐of‐life changes continue well beyond the first postoperative year, with one‐year complications emerging as the strongest potentially modifiable predictor of later decline.

Commentary: Acupoint glucocorticoid injection combined with focused ultrasound for granulomatous lobular mastitis: a retrospective study

DOJ announces first health care company declination

Campus Eye avoided prosecution after voluntarily disclosing misconduct, cooperating with investigators, and remediating the wrongdoing.